Advanced search
Publication Cover
Molecular and Cellular Biology Volume 15, 1995 - Issue 12
Submit an article Journal homepage
5
Views
169
CrossRef citations to date
0
Altmetric
Research Article

Evidence that Farnesyltransferase Inhibitors Suppress Ras Transformation by Interfering with Rho Activity

Peter F. Lebowitz1 The Wistar Institute, Philadelphia, Pennsylvania19104
,
Joseph P. Davide2 Department of Cancer Research, Merck Research Laboratories, West Point, Pennsylvania19486
&
George C. Prendergast1 The Wistar Institute, Philadelphia, Pennsylvania19104;3 Department of Genetics, University of Pennsylvania, Philadelphia, Pennsylvania19104Correspondence[email protected]
Pages 6613-6622 | Received 04 Apr 1995, Accepted 19 Sep 1995, Published online: 30 Mar 2023

Citations (169)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (16)

Irene Dehghan-Paz, Dora Il’yasova, Kenneth L van Golen & Lydia Usha. (2013) Tipifarnib and farnesyltransferase inhibitors in the treatment of inflammatory breast cancer: is the story over? A review. Orphan Drugs: Research and Reviews 3, pages 11-21.
Read now
Michel Vulfovich & Nabil Saba. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 13:6, pages 577-607.
Read now
Grace K. Dy & Alex A. Adjei. (2002) Farnesyltransferase Inhibitors in Breast Cancer Therapy. Cancer Investigation 20:sup2, pages 30-37.
Read now
Desirée Hao & Eric K. Rowinsky. (2002) Inhibiting Signal Transduction: Recent Advances in the Development of Receptor Tyrosine Kinase and Ras Inhibitors. Cancer Investigation 20:3, pages 387-404.
Read now
Neena Rane & George C Prendergast. (2001) Farnesyltransferase inhibitors: mechanism and applications. Expert Opinion on Investigational Drugs 10:12, pages 2105-2116.
Read now
Saïd M Sebti & Andrew D Hamilton. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opinion on Investigational Drugs 9:12, pages 2767-2782.
Read now
Ai-xue Liu, Wei Du, Jeh-Ping Liu, Thomas M. Jessell & George C. Prendergast. (2000) RhoB Alteration Is Necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors. Molecular and Cellular Biology 20:16, pages 6105-6113.
Read now
Eric K Rowinsky & Amita Patnaik. (2000) The development of protein farnesyltransferase and other ras-directed therapeutics for malignant diseases. Emerging Drugs 5:2, pages 161-199.
Read now
Kun Jiang, Domenico Coppola, Nichole C. Crespo, Santo V. Nicosia, Andrew D. Hamilton, Said M. Sebti & Jin Q. Cheng. (2000) The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis. Molecular and Cellular Biology 20:1, pages 139-148.
Read now
Wei Du, Peter F. Lebowitz & George C. Prendergast. (1999) Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB. Molecular and Cellular Biology 19:3, pages 1831-1840.
Read now
Peter F. Lebowitz & George C. Prendergast. (1998) Functional interaction between RhoB and the transcription factor DB1. Cell Adhesion and Communication 6:4, pages 277-287.
Read now
Rebecca E. Barrington, Mark A. Subler, Elaine Rands, Charles A. Omer, Patricia J. Miller, Jeffrey E. Hundley, Steven K. Koester, Dean A. Troyer, David J. Bearss, Michael W. Conner, Jackson B. Gibbs, Kelly Hamilton, Kenneth S. Koblan, Scott D. Mosser, Timothy J. O’Neill, Michael D. Schaber, Edith T. Senderak, Jolene J. Windle, Allen Oliff & Nancy E. Kohl. (1998) A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis. Molecular and Cellular Biology 18:1, pages 85-92.
Read now
Samuel L Graham & Theresa M Williams. (1996) Patent Update Oncologic, Endocrine & Metabolic: Oncologic, Endocrine & Metabolic: Inhibitors of protein farnesylation. Expert Opinion on Therapeutic Patents 6:12, pages 1295-1304.
Read now
Jiri Lukas, Jirina Bartkova & Jiri Bartek. (1996) Convergence of Mitogenic Signalling Cascades from Diverse Classes of Receptors at the Cyclin D–Cyclin-Dependent Kinase–pRb-Controlled G1 Checkpoint. Molecular and Cellular Biology 16:12, pages 6917-6925.
Read now
L. Masuelli & M. L. Cutler. (1996) Increased Expression of the Ras Suppressor Rsu-1 Enhances Erk-2 Activation and Inhibits Jun Kinase Activation. Molecular and Cellular Biology 16:10, pages 5466-5476.
Read now
D. Perrin, S. Halazy & B. T. Hill. (1996) Inhibitors of the Ras Signal Transduction Pathway as Potential Antitumour Agentsx. Journal of Enzyme Inhibition 11:2, pages 77-95.
Read now

Articles from other publishers (153)

Cristiana Lungu, Florian Meyer, Marcel Hörning, Jasmin Steudle, Anja Braun, Bettina Noll, David Benz, Felix Fränkle, Simone Schmid, Stephan A. Eisler & Monilola A. Olayioye. (2023) Golgi screen identifies the RhoGEF Solo as a novel regulator of RhoB and endocytic transport . Traffic 24:4, pages 162-176.
Crossref
Maho Miyauchi, Reina Matsumura & Hiroyuki Kawahara. (2023) BAG6 supports stress fiber formation by preventing the ubiquitin-mediated degradation of RhoA. Molecular Biology of the Cell 34:4.
Crossref
Fabienne Podieh, Roos Wensveen, Max C. Overboom, Lotte Abbas, Jisca Majolée & Peter L. Hordijk. (2023) Differential role for rapid proteostasis in Rho GTPase-mediated control of quiescent endothelial integrity. Journal of Biological Chemistry 299:4, pages 104593.
Crossref
Linda Kessler, Shivani Malik, Mollie Leoni & Francis Burrows. (2021) Potential of Farnesyl Transferase Inhibitors in Combination Regimens in Squamous Cell Carcinomas. Cancers 13:21, pages 5310.
Crossref
Jie Ding, Yu X. Chen, Yan Chen, Yun Mou, Xiao T. Sun, Dong P. Dai, Chen Z. Zhao, Jian Yang, Shen J. Hu & Xiaogang Guo. (2020) Overexpression of FNTB and the activation of Ras induce hypertrophy and promote apoptosis and autophagic cell death in cardiomyocytes. Journal of Cellular and Molecular Medicine 24:16, pages 8998-9011.
Crossref
Sean Porazinski, Ashleigh Parkin & Marina Pajic. 2020. Tumor Microenvironment. Tumor Microenvironment 99 127 .
Lok Ming Tam, Ming Huang & Yinsheng Wang. (2019) Targeted Quantitative Proteomics Revealed Arsenite-induced Proteasomal Degradation of RhoB in Fibroblast Cells. Chemical Research in Toxicology 32:7, pages 1343-1350.
Crossref
Julia Ju & Daniele Gilkes. (2018) RhoB: Team Oncogene or Team Tumor Suppressor?. Genes 9:2, pages 67.
Crossref
Helena Gbelcová, Silvie Rimpelová, Tomáš Ruml, Marie Fenclová, Vítek Kosek, Jana Hajšlová, Hynek Strnad, Michal Kolář & Libor Vítek. (2017) Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Scientific Reports 7:1.
Crossref
Yufang Ma, Yuanying Gong, Zhixiang Cheng, Sudan Loganathan, Crystal Kao, Jann N. Sarkaria, Ty W. Abel & Jialiang Wang. (2015) Critical functions of RhoB in support of glioblastoma tumorigenesis. Neuro-Oncology 17:4, pages 516-525.
Crossref
Daphna Mokady & David Meiri. (2015) RhoGTPases – A novel link between cytoskeleton organization and cisplatin resistance. Drug Resistance Updates 19, pages 22-32.
Crossref
Stefanie C. Huelsenbeck, Dennis Roggenkamp, Martin May, Johannes Huelsenbeck, Cord Brakebusch, Klemens Rottner, Markus Ladwein, Ingo Just, Gerhard Fritz, Gudula Schmidt & Harald Genth. (2013) Expression and cytoprotective activity of the small GTPase RhoB induced by the Escherichia coli cytotoxic necrotizing factor 1. The International Journal of Biochemistry & Cell Biology 45:8, pages 1767-1775.
Crossref
Claire Médale-Giamarchi, Isabelle Lajoie-Mazenc, Emilie Malissein, Elise Meunier, Bettina Couderc, Yann Bergé, Thomas Filleron, Laura Keller, Claudine Marty, Magali Lacroix-Triki, Florence Dalenc, Sophie F Doisneau-Sixou & Gilles Favre. (2013) RhoB modifies estrogen responses in breast cancer cells by influencing expression of the estrogen receptor. Breast Cancer Research 15:1.
Crossref
Doona Song, Jee Sun Yang, Seo Joong Kim, Bo-Kyung Kim, Song-Kyu Park, Misun Won, Kiho Lee, Hwan Mook Kim, Kang-Yell Choi, Kyeong Lee & Gyoonhee Han. (2013) Design, synthesis and biological evaluation of novel aliphatic amido/sulfonamido-quaternary ammonium salts as antitumor agents. Bioorganic & Medicinal Chemistry 21:3, pages 788-794.
Crossref
Johannes Huelsenbeck, Martin May, Florian Schulz, Ilona Schelle, Natalia Ronkina, Martin Hohenegger, Gerhard Fritz, Ingo Just, Ralf Gerhard & Harald Genth. (2012) Cytoprotective effect of the small GTPase RhoB expressed upon treatment of fibroblasts with the Ras-glucosylating Clostridium sordellii lethal toxin . FEBS Letters 586:20, pages 3665-3673.
Crossref
Seung Hyun Oh, Ju-Hee Kang, Jong Kyu Woo, Ok-Hee Lee, Edward S. Kim & Ho-Young Lee. (2012) A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer. International Journal of Cancer 131:3, pages 537-547.
Crossref
Daniela Alfano, Pia Ragno, M. Patrizia Stoppelli & Anne J. Ridley. (2012) RhoB regulates uPAR signalling. Journal of Cell Science.
Crossref
Marta A. S. Perez, Sérgio F. Sousa, Eduardo F. T. Oliveira, Pedro A. Fernandes & Maria J. Ramos. (2011) Detection of Farnesyltransferase Interface Hot Spots through Computational Alanine Scanning Mutagenesis. The Journal of Physical Chemistry B 115:51, pages 15339-15354.
Crossref
Moumita Chaterjee & Kenneth L. van Golen. (2011) Breast Cancer Stem Cells Survive Periods of Farnesyl-Transferase Inhibitor-Induced Dormancy by Undergoing Autophagy. Bone Marrow Research 2011, pages 1-7.
Crossref
Moumita Chatterjee & Kenneth L. van Golen. (2011) Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype. International Journal of Cancer 129:1, pages 61-69.
Crossref
Minzhou Huang, Lauren Satchell, James B. DuHadaway, George C. Prendergast & Lisa D. Laury-Kleintop. (2011) RhoB links PDGF signaling to cell migration by coordinating activation and localization of Cdc42 and Rac. Journal of Cellular Biochemistry 112:6, pages 1572-1584.
Crossref
W. Robert Bishop, Ronald Doll & Paul Kirschmeier. 2011. Protein Prenylation PART A. Protein Prenylation PART A 275 303 .
Minzhou Huang, Lisa D. Laury-Kleintop & George C. Prendergast. 2010. The Rho GTPases in Cancer. The Rho GTPases in Cancer 135 153 .
Kenneth van Golen. 2010. The Rho GTPases in Cancer. The Rho GTPases in Cancer 123 134 .
Florence Grise, Aurélien Bidaud & Violaine Moreau. (2009) Rho GTPases in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1795:2, pages 137-151.
Crossref
Ioannis KotsianidisEvangelia NakouIrene Bouchliou. (2009) Pharmacotherapy of Hematologic Malignancies with Tipifarnib. Clinical Medicine. Therapeutics 1, pages CMT.S1097.
Crossref
Sachiko Maeda, Kazuho Sakamoto, Isao Matsuoka, Takahiro Iwamoto & Junko Kimura. (2009) Lysophosphatidylcholine Increases Na+/Ca2+ Exchanger Expression via RhoB-Geranylgeranylation in H9c2 Cells. Journal of Pharmacological Sciences 109:4, pages 565-572.
Crossref
Alejandra C. VenturaSofia D. Merajver. (2008) Genetic Determinants of Aggressive Breast Cancer. Annual Review of Medicine 59:1, pages 199-212.
Crossref
Isabelle Lajoie-Mazenc, Daniel Tovar, Marie Penary, Barbara Lortal, Sophie Allart, Cyril Favard, Meryem Brihoum, Anne Pradines & Gilles Favre. (2008) MAP1A Light Chain-2 Interacts with GTP-RhoB to Control Epidermal Growth Factor (EGF)-dependent EGF Receptor Signaling. Journal of Biological Chemistry 283:7, pages 4155-4164.
Crossref
Julien Mazières, Daniel Tovar, Biao He, Jacobo Nieto-Acosta, Claire Marty-Detraves, Carine Clanet, Anne Pradines, David Jablons & Gilles Favre. (2007) Epigenetic regulation of RhoB loss of expression in lung cancer. BMC Cancer 7:1.
Crossref
Reinhard E. MarksAllen W. HoChristian RobbelTodd KunaSeth Berk & Thomas F. Gajewski. (2007) Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood 110:6, pages 1982-1988.
Crossref
Aryeh M. Abeles, Nada Marjanovic, Jean Park, Mukundan Attur, Edwin S. Chan, Hayf E. Al-Mussawir, Mandar Dave, Mark C. Fisher, Steven A. Stuchin, Steven B. Abramson & Michael H. Pillinger. (2007) Protein isoprenylation regulates secretion of matrix metalloproteinase 1 from rheumatoid synovial fibroblasts: Effects of statins and farnesyl and geranylgeranyl transferase inhibitors. Arthritis & Rheumatism 56:9, pages 2840-2853.
Crossref
Xosé R. Bustelo, Vincent Sauzeau & Inmaculada M. Berenjeno. (2007) GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. BioEssays 29:4, pages 356-370.
Crossref
P. Fumoleau, M. Campone, B. Coudert, F. Mayer, L. Favier & E. Ferrant. 2007. Cancer du sein. Cancer du sein 453 498 .
Jeffrey E. Lancet. 2007. Acute Myelogenous Leukemia. Acute Myelogenous Leukemia 263 274 .
Aram F. Hezel, Alec C. Kimmelman, Ben Z. Stanger, Nabeel Bardeesy & Ronald A. DePinho. (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Development 20:10, pages 1218-1249.
Crossref
Alex A. Adjei. (2006) Farnesyltransferase inhibitors. Update on Cancer Therapeutics 1:1, pages 17-23.
Crossref
Andrea D. Basso, Paul Kirschmeier & W. Robert Bishop. (2006) Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors. Journal of Lipid Research 47:1, pages 15-31.
Crossref
Joydeep Mukherjee & Abhijit Guha. 2006. Handbook of Brain Tumor Chemotherapy. Handbook of Brain Tumor Chemotherapy 173 184 .
P. Fumoleau, M. Campone, N. Isambert, E. Bourbouloux, F. Mayer & B. Coudert. 2006. Cancer du sein. Cancer du sein 233 266 .
Jennifer Y Kong & Simon W Rabkin. (2005) The association between RhoB and caspase-2: changes with lovastatin-induced apoptosis. Biochemistry and Cell Biology 83:5, pages 608-619.
Crossref
Sachiko Maeda, Isao Matsuoka, Takahiro Iwamoto, Hitoshi Kurose & Junko Kimura. (2005) Down-Regulation of Na + /Ca 2+ Exchanger by Fluvastatin in Rat Cardiomyoblast H9c2 Cells: Involvement of RhoB in Na + /Ca 2+ Exchanger mRNA Stability . Molecular Pharmacology 68:2, pages 414-420.
Crossref
Hening Ren, Shyh-Kuan Tai, Fadlo Khuri, Zuming Chu & Li Mao. (2005) Farnesyltransferase Inhibitor SCH66336 Induces Rapid Phosphorylation of Eukaryotic Translation Elongation Factor 2 in Head and Neck Squamous Cell Carcinoma Cells. Cancer Research 65:13, pages 5841-5847.
Crossref
Josep Tabernero, Fredy Rojo, Irene Marimón, Maurizio Voi, Joan Albanell, Marta Guix, Federico Vázquez, Joan Carulla, Michael Cooper, Jordi Andreu, Anne Van Vreckem, Joaquim Bellmunt, Veeraswamy Manne, James A. Manning, Carmen Garrido, Enriqueta Felip, Josep Maria del Campo, Mónica García, Sonia Valverde & José Baselga. (2005) Phase I Pharmacokinetic and Pharmacodynamic Study of Weekly 1-Hour and 24-Hour Infusion BMS-214662, a Farnesyltransferase Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology 23:11, pages 2521-2533.
Crossref
Julien Mazières, Vanessa Tillement, Cuider Allal, Carine Clanet, Lisbeth Bobin, Zhi Chen, Said M. Sebti, Gilles Favre & Anne Pradines. (2005) Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Experimental Cell Research 304:2, pages 354-364.
Crossref
Nieves Mijimolle, Juan Velasco, Pierre Dubus, Carmen Guerra, Carolyn A. Weinbaum, Patrick J. Casey, Victoria Campuzano & Mariano Barbacid. (2005) Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell 7:4, pages 313-324.
Crossref
Lina Vardouli, Aristidis Moustakas & Christos Stournaras. (2005) LIM-kinase 2 and Cofilin Phosphorylation Mediate Actin Cytoskeleton Reorganization Induced by Transforming Growth Factor-β. Journal of Biological Chemistry 280:12, pages 11448-11457.
Crossref
Ph. Cestac, S. Doisneau-Sixou & G. Favre. (2005) Développement des inhibiteurs de farnésyl transférase comme agents anticancéreux. Annales Pharmaceutiques Françaises 63:1, pages 76-84.
Crossref
Matthew Wherlock, Alexandra Gampel, Clare Futter & Harry Mellor. (2004) Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. Journal of Cell Science 117:15, pages 3221-3231.
Crossref
Julien Mazieres, Anne Pradines & Gilles Favre. (2004) Perspectives on farnesyl transferase inhibitors in cancer therapy. Cancer Letters 206:2, pages 159-167.
Crossref
Li Mao, Waun K Hong & Vassiliki A Papadimitrakopoulou. (2004) Focus on head and neck cancer. Cancer Cell 5:4, pages 311-316.
Crossref
Anita F.W. Frijhoff, Claudio J. Conti & Adrian M. Senderowicz. (2004) Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs. Molecular Carcinogenesis 39:4, pages 183-194.
Crossref
Krister Wennerberg & Channing J. Der. (2004) Rho-family GTPases: it's not only Rac and Rho (and I like it). Journal of Cell Science 117:8, pages 1301-1312.
Crossref
Min Lin & Kenneth L. van Golen. (2004) Rho-Regulatory Proteins in Breast Cancer Cell Motility and Invasion. Breast Cancer Research and Treatment 84:1, pages 49-60.
Crossref
Kun Jiang, Frederic L Delarue & Saïd M Sebti. (2003) EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 23:5, pages 1136-1145.
Crossref
Jeffrey E. LancetJudith E. Karp. (2003) Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102:12, pages 3880-3889.
Crossref
María Sereno Moyano, Enrique Espinosa Arranz, Beatriz Castelo Fernández & Manuel González Barón. (2003) Biología Molecular de los cánceres de cabeza y cuelloMolecular Biology in head and neck cancer. Revista de Oncología 5:9, pages 500-510.
Crossref
Irit Adini, Isaac Rabinovitz, Jing Fang Sun, George C. Prendergast & Laura E. Benjamin. (2003) RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development. Genes & Development 17:21, pages 2721-2732.
Crossref
Tom Malcolm, Elham Ettehadieh & Ivan Sadowski. (2003) Mitogen-responsive expression of RhoB is regulated by RNA stability. Oncogene 22:40, pages 6142-6150.
Crossref
Alex A Adjei. (2003) An overview of farnesyltransferase inhibitors and their role in lung cancer therapy. Lung Cancer 41, pages 55-62.
Crossref
James B DuHadaway, Wei Du, Scott Donover, Judith Baker, Ai–xue Liu, Diane M Sharp, Alexander J Muller & George C Prendergast. (2003) Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1. Oncogene 22:23, pages 3578-3588.
Crossref
John Greenwood, Claire E. Walters, Gareth Pryce, Naheed Kanuga, Evelyne Bemud, David Baker & Peter Adamson. (2003) Lovastatin inhibits brain endothelial cell Rho‐mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. The FASEB Journal 17:8, pages 1-16.
Crossref
Ping-Yao Zeng, Neena Rane, Wei Du, Janaki Chintapalli & George C Prendergast. (2003) Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene 22:8, pages 1124-1134.
Crossref
Julien Mazières, Anne Pradines & Gilles Favre. (2003) Les inhibiteurs de farnésyl transférase : une cible peut en cacher une autre. médecine/sciences 19:2, pages 211-216.
Crossref
Alex A. Adjei. 2003. 127 144 .
E. J. Bernhard, A. K. Gupta, S. M. Hahn, W. G. Mckenna & R. J. Muschel. 2003. Modification of Radiation Response. Modification of Radiation Response 259 274 .
Walter L. Vervenne, Carina L. Bos, Linda S. Rens, Maikel P. Peppelenbosch & Dick J. Richel. (2002) Farnesyl Protein Transferase Inhibition Interferes with Activation of MAP Kinase Family Members in Human Peripheral Blood Monocytes. Molecular Medicine 8:12, pages 857-862.
Crossref
Raymond R. Mattingly, Richard A. Gibbs, Raymond E. Menard & John J. ReinersJr.Jr.. (2002) Potent Suppression of Proliferation of A10 Vascular Smooth Muscle Cells by Combined Treatment with Lovastatin and 3-Allylfarnesol, an Inhibitor of Protein Farnesyltransferase. Journal of Pharmacology and Experimental Therapeutics 303:1, pages 74-81.
Crossref
P Haluska, G.K Dy & A.A Adjei. (2002) Farnesyl transferase inhibitors as anticancer agents. European Journal of Cancer 38:13, pages 1685-1700.
Crossref
Grace K. Dy & Alex A. Adjei. (2002) The Role of Farnesyltransferase Inhibitors in Lung Cancer Therapy. Clinical Lung Cancer 4:1, pages 57-62.
Crossref
W.Gillies McKenna, Ruth J. Muschel, Anjali K. Gupta, Stephen M. Hahn & Eric J. Bernhard. (2002) Farnesyltransferase inhibitors as radiation sensitizers. Seminars in Radiation Oncology 12:3, pages 27-32.
Crossref
Edward S. Kim, Merrill Kies & Roy S. Herbst. (2002) Novel therapeutics for head and neck cancer. Current Opinion in Oncology 14:3, pages 334-342.
Crossref
M. M. Moasser & Neal Rosen. (2002) The Use of Molecular Markers in Farnesyltransferase Inhibitor (FTI) Therapy of Breast Cancer. Breast Cancer Research and Treatment 73:2, pages 135-144.
Crossref
Claire E. Walters, Gareth Pryce, Deborah J. R. Hankey, Said M. Sebti, Andrew D. Hamilton, David Baker, John Greenwood & Peter Adamson. (2002) Inhibition of Rho GTPases with Protein Prenyltransferase Inhibitors Prevents Leukocyte Recruitment to the Central Nervous System and Attenuates Clinical Signs of Disease in an Animal Model of Multiple Sclerosis. The Journal of Immunology 168:8, pages 4087-4094.
Crossref
Jalila Adnane, Edward Seijo, Zhi Chen, Francisco Bizouarn, Martha Leal, Said M. Sebti & Teresita Muñoz-Antonia. (2002) RhoB, Not RhoA, Represses the Transcription of the Transforming Growth Factor β Type II Receptor by a Mechanism Involving Activator Protein 1. Journal of Biological Chemistry 277:10, pages 8500-8507.
Crossref
Carlos L Arteaga, Fadlo Khuri, Geoffrey Krystal & Said Sebti. (2002) Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology 29:1, pages 15-26.
Crossref
Herbert I. Hurwitz & Patrick J. Casey. 2002. Peptide-Lipid Interactions. Peptide-Lipid Interactions 531 550 .
Aron B. Jaffe & Alan Hall. 2002. 57 80 .
Hiroshi Maruta, Hong He & Thao Nheu. 2002. Tumor Suppressing Viruses, Genes, and Drugs. Tumor Suppressing Viruses, Genes, and Drugs 361 377 .
George C. Prendergast. 2002. Tumor Suppressing Viruses, Genes, and Drugs. Tumor Suppressing Viruses, Genes, and Drugs 293 309 .
Eric K. Rowinsky. 2002. Colorectal Cancer. Colorectal Cancer 759 793 .
George C. Prendergast. (2001) Actin' up: RhoB in cancer and apoptosis. Nature Reviews Cancer 1:2, pages 162-168.
Crossref
Mackenzie L. De Vos, David S. Lawrence & Charles D. Smith. (2001) Cellular pharmacology of cerulenin analogs that inhibit protein palmitoylation11Abbreviations: FT-IR, Fourier transform infrared; THF, tetrahydrofuran; FBS, fetal bovine serum; FPTase, farnesyl protein transferase; PPTase, protein palmitoyltransferase; FTI, farnesyl transferase inhibitor; DTT, dithiothreitol.. Biochemical Pharmacology 62:8, pages 985-995.
Crossref
Isabel Laplante, Joanne Paquin & Richard Béliveau. (2001) RhoB expression is induced after the transient upregulation of RhoA and Cdc42 during neuronal differentiation and influenced by culture substratum and microtubule integrity. Developmental Brain Research 129:2, pages 157-168.
Crossref
Ai-xue Liu, George J. Cerniglia, Eric J. Bernhard & George C. Prendergast. (2001) RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proceedings of the National Academy of Sciences 98:11, pages 6192-6197.
Crossref
Lucia Vigano, Alberta Locatelli, Giacomo Grasselli & Luca Gianni. (2001) Drug Interactions of Paclitaxel and Docetaxel and their Relevance for the Design of Combination Therapy. Investigational New Drugs 19:2, pages 179-196.
Crossref
M Crul, G J de Klerk, J H Beijnen & J HM Schellens. (2001) Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anti-Cancer Drugs 12:3, pages 163-184.
Crossref
Saïd M Sebti & Andrew D Hamilton. (2000) Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene 19:56, pages 6584-6593.
Crossref
Hadas Reuveni, Tamar Geiger, Benjamin Geiger & Alexander Levitzki. (2000) Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway. Journal of Cell Biology 151:6, pages 1179-1192.
Crossref
George C Prendergast & Allen Oliff. (2000) Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. Seminars in Cancer Biology 10:6, pages 443-452.
Crossref
Alfred Wittinghofer & Herbert Waldmann. (2000) Ras—A Molecular Switch Involved in Tumor Formation. Angewandte Chemie 39:23, pages 4192-4214.
Crossref
Alfred Wittinghofer & Herbert Waldmann. (2000) Ras – ein molekularer Schalter bei der Tumorentstehung. Angewandte Chemie 112:23, pages 4360-4383.
Crossref
F.A.L.M. Eskens, G. Stoter & J. Verweij. (2000) Farnesyl transferase inhibitors: current developments and future perspectives. Cancer Treatment Reviews 26:5, pages 319-332.
Crossref
Anjali Tikoo, Suzanne Czekay, Carrie Viars, Sara White, Joan K Heath, Karen Arden & Hiroshi Maruta. (2000) p190-A, a human tumor suppressor gene, maps to the chromosomal region 19q13.3 that is reportedly deleted in some gliomas. Gene 257:1, pages 23-31.
Crossref
Ai-xue Liu & George C. Prendergast. (2000) Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Letters 481:3, pages 205-208.
Crossref
Christoph W. M. ReuterMichael A. MorganLothar Bergmann. (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 96:5, pages 1655-1669.
Crossref
Christoph W. M. ReuterMichael A. MorganLothar Bergmann. (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 96:5, pages 1655-1669.
Crossref
Elizabeth Cohen-Jonathan, Ruth J. Muschel, W. Gillies McKenna, Sydney M. Evans, George Cerniglia, Rosemarie Mick, Donna Kusewitt, Said M. Sebti, Andrew D. Hamilton, Allen Oliff, Nancy Kohl, Jackson B. Gibbs & Eric J. Bernhard. (2000) Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS 1 . Radiation Research 154:2, pages 125-132.
Crossref
Friederike C. von Lintig, Anna D. Dreilinger, Nissi M. Varki, Anne M. Wallace, Darren E. Casteel & Gerry R. Boss. (2000) Ras activation in human breast cancer. Breast Cancer Research and Treatment 62:1, pages 51-62.
Crossref
Si Young Song, Ingrid M. Meszoely, Robert J. Coffey, Jennifer A. Pietenpo & Steven D. Leach. (2000) K-Ras-Independent Effects of the Farnesyl Transferase Inhibitor L-744,832 on Cyclin B1/Cdc2 Kinase Activity, G2/M Cell Cycle Progression and Apoptosis in Human Pancreatic Ductal Adenocarcinoma Cell. Neoplasia 2:3, pages 261-272.
Crossref
F. Vasaturo, G.W. Dougherty & M.L. Cutler. (2000) Ectopic expression of Rsu-1 results in elevation of p21CIP and inhibits anchorage-independent growth of MCF7 breast cancer cells. Breast Cancer Research and Treatment 61:1, pages 69-78.
Crossref
George C Prendergast. (2000) Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Current Opinion in Cell Biology 12:2, pages 166-173.
Crossref
Luisa Lucas, Luis del Peso, Pilar Rodríguez, Verónica Penalva & Juan Carlos Lacal. (2000) Ras protein is involved in the physiological regulation of phospholipase D by platelet derived growth factor. Oncogene 19:3, pages 431-437.
Crossref
Peter D. EmanuelRichard C. SnyderTonya WileyBalaganesh GopuralaRobert P. Castleberry. (2000) Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95:2, pages 639-645.
Crossref
Wouter Van't Hof & Marilyn D. Resh. 2000. Applications of Chimeric Genes and Hybrid Proteins - Part B: Cell Biology and Physiology. Applications of Chimeric Genes and Hybrid Proteins - Part B: Cell Biology and Physiology 317 330 .
Dominique Perrin & Bridget T. Hill. 2000. New Approaches to Drug Development. New Approaches to Drug Development 153 179 .
Herbert Waldmann & Michael Thutewohl. 2001. Bioorganic Chemistry of Biological Signal Transduction. Bioorganic Chemistry of Biological Signal Transduction 117 130 .
Carol S. Trempus, W. Robert Bishop, F. George Njoroge, Ronald J. Doll, Michael StJ. Battalora, Joel F. Mahler, Joseph K. Haseman & Raymond W. Tennant. (2000) A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse. Molecular Carcinogenesis 27:1, pages 24-33.
Crossref
M S A Nur-E-Kamal, J M Kamal, M M Qureshi & H Maruta. (2000) The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-induced transformation. Oncogene 18:54, pages 7787-7793.
Crossref
Matthias M Feldkamp, Nelson Lau & Abhijit Guha. (1999) Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 18:52, pages 7514-7526.
Crossref
HIROSHI MARUTA, HONG HE, ANJALI TIKOO & MSA NUR-E-KAMAL. (1999) Cytoskeletal Tumor Suppressors That Block Oncogenic RAS Signaling. Annals of the New York Academy of Sciences 886:1 ANTICANCER MO, pages 48-57.
Crossref
Eric K. RowinskyJolene J. WindleDaniel D. Von Hoff. (1999) Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development. Journal of Clinical Oncology 17:11, pages 3631-3652.
Crossref
Kenneth J. Henry,, James Wasicak, Andrew S. Tasker, Jerome Cohen, Patricia Ewing, Michael Mitten, John J. Larsen, Douglas M. Kalvin, Rolf Swenson, Shi-Chung Ng, Badr Saeed, Sajeev Cherian, Hing Sham & Saul H. Rosenberg. (1999) Discovery of a Series of Cyclohexylethylamine-Containing Protein Farnesyltransferase Inhibitors Exhibiting Potent Cellular Activity. Journal of Medicinal Chemistry 42:23, pages 4844-4852.
Crossref
Nidal MahgoubBrigit R. TaylorMary GratiotNancy E. KohlJackson B. GibbsTyler JacksKevin M. Shannon. (1999) In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor onNf1-Deficient Hematopoietic Cells. Blood 94:7, pages 2469-2476.
Crossref
Hidekazu Tanaka, Kazuyo Nishida, Kenji Sugita & Takayuki Yoshioka. (1999) Antitumor Efficacy of Hypothemycin, A New Ras-signaling Inhibitor. Japanese Journal of Cancer Research 90:10, pages 1139-1145.
Crossref
Banke Agarwal, Chinthalapally V. Rao, Sanjay Bhendwal, William R. Ramey, Haim Shirin, Bandaru S. Reddy & Peter R. Holt. (1999) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117:4, pages 838-847.
Crossref
Hiroshi Maruta, Hong He, Anjali Tikoo, Thao Vuong & MSA Nur-E-Kamal. (1999) G proteins, phosphoinositides, and actin-cytoskeleton in the control of cancer growth. Microscopy Research and Technique 47:1, pages 61-66.
Crossref
Ágnes Sebök, Nóra Nusser, Balázs Debreceni, Zhong Guo, Marinilce F. Santos, József Szeberenyi & Gábor Tigyi. (2001) Different Roles for RhoA During Neurite Initiation, Elongation, and Regeneration in PC12 Cells. Journal of Neurochemistry 73:3, pages 949-960.
Crossref
Enrique Poradosu, Aviv Gazit, Hadas Reuveni & Alexander Levitzki. (1999) α-Cyanocinnamide derivatives: a new family of non-peptide, non-sulfhydryl inhibitors of ras farnesylation. Bioorganic & Medicinal Chemistry 7:8, pages 1727-1736.
Crossref
Wei Wang & Robert J.B. MaCaulay. (1999) Apoptosis of medulloblastoma cellsIn vitro follows inhibition of farnesylation using manumycin A. International Journal of Cancer 82:3, pages 430-434.
Crossref
George C Prendergast. (1999) Mechanisms of apoptosis by c-Myc. Oncogene 18:19, pages 2967-2987.
Crossref
Allen Oliff. (1999) Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1423:3, pages C19-C30.
Crossref
George C. Prendergast & Wei Du. (1999) Targeting farnesyltransferase: is Ras relevant?. Drug Resistance Updates 2:2, pages 81-84.
Crossref
Toshihiko Nagase, Sumio Kawata, Hiromu Nakajima, Shinji Tamura, Eiji Yamasaki, Koji Fukui, Koji Yamamoto, Jun-ichiro Miyagawa, Itaru Matsumura, Yukihiko Matsuda & Yuji Matsuzawa. (1999) Effect of farnesyltransferase overexpression on cell growth and transformation. International Journal of Cancer 80:1, pages 126-133.
Crossref
Theresa M. Williams & Christopher J. Dinsmore. 1999. 273 314 .
Benjamin Boettner & Linda Van Aelst. 1999. Cytoskeleton and Small G Proteins. Cytoskeleton and Small G Proteins 135 158 .
Anne J. Ridley. 1999. Cytoskeleton and Small G Proteins. Cytoskeleton and Small G Proteins 1 22 .
Kevin G. Waddick & Fatih M. Uckun. (1998) Innovative treatment programs against cancer. Biochemical Pharmacology 56:11, pages 1411-1426.
Crossref
Nobutaka Suzuki, Keith Del Villar & Fuyuhiko Tamanoi. (1998) Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proceedings of the National Academy of Sciences 95:18, pages 10499-10504.
Crossref
Patricia Servais, Béatrice Gulbis, Dominique Fokan & Paul Galand. (1998) Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells. International Journal of Cancer 76:4, pages 601-608.
Crossref
Klaus Hinterding, Patrizia Hagenbuch, Janos Rétey & Herbert Waldmann. (1998) Synthese und In-vitro-Evaluierung des Ras-Farnesyltransferase-Inhibitors Pepticinnamin E. Angewandte Chemie 110:9, pages 1298-1301.
Crossref
Michael E. Engel, Pran K. Datta & Harold L. Moses. (1998) RhoB Is Stabilized by Transforming Growth Factor β and Antagonizes Transcriptional Activation. Journal of Biological Chemistry 273:16, pages 9921-9926.
Crossref
Alan K. Mallams, Randall R. Rossman, Ronald J. Doll, Viyyoor M. Girijavallabhan, Ashit K. Ganguly, Joanne Petrin, Lynn Wang, Robert Patton, W. Robert Bishop, Donna M. Carr, Paul Kirschmeier, Joseph J. Catino, Matthew S. Bryant, Kwang-Jong Chen, Walter A. Korfmacher, Cymbelene Nardo, Shiyong Wang, Amin A. Nomeir, Chin-Chung Lin, Zujun Li, Jianping Chen, Suining Lee, Janet Dell, Philip Lipari, Michael Malkowski, Bodan Yaremko, Ivan King & Ming Liu. (1998) Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5 H -benzo[5,6]- cyclohepta[1,2- b ]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11- dihydro-5 H -benzo[5,6]cyclohepta[1,2- b ]pyridin-11-yl)piperazine . Journal of Medicinal Chemistry 41:6, pages 877-893.
Crossref
Mark M. Moasser, Laura Sepp-Lorenzino, Nancy E. Kohl, Allen Oliff, Aaron Balog, Dai-Shi Su, Samuel J. Danishefsky & Neal Rosen. (1998) Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proceedings of the National Academy of Sciences 95:4, pages 1369-1374.
Crossref
Robert B. Lobell. 1998. Advances in Immunology Volume 68. Advances in Immunology Volume 68 145 189 .
A.J. Ridley. (1997) The GTP-binding protein Rho. The International Journal of Biochemistry & Cell Biology 29:11, pages 1225-1229.
Crossref
Javier Gómez, Carlos Martínez-A.Murielle Giry, Alphonse García & Angelita Rebollo. (1997) Rho prevents apoptosis through Bcl-2 expression: Implications for interleukin-2 receptor signal transduction. European Journal of Immunology 27:11, pages 2793-2799.
Crossref
François Vrtovsnik, Sylviane Couette, Dominique Prié, Dominique Lallemand & Gérard Friedlander. (1997) Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21 activated, AP-1-dependent pathway. Kidney International 52:4, pages 1016-1027.
Crossref
Cynthia Evans Trueblood, Victor L. Boyartchuk & Jasper Rine. (1997) Substrate specificity determinants in the farnesyltransferase β-subunit. Proceedings of the National Academy of Sciences 94:20, pages 10774-10779.
Crossref
Daniele M. Leonard. (1997) Ras Farnesyltransferase:  A New Therapeutic Target. Journal of Medicinal Chemistry 40:19, pages 2971-2990.
Crossref
G. F. Clunn, J. S. Lymn, M Schachter & A. D. Hughes. (1997) Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells. British Journal of Pharmacology 121:8, pages 1789-1795.
Crossref
Jackson B Gibbs, Samuel L Graham, George D Hartman, Kenneth S Koblan, Nancy E Kohl, Charles A Omer & Allen Oliff. (1997) Farnesyltransferase inhibitors versus Ras inhibitors. Current Opinion in Chemical Biology 1:2, pages 197-203.
Crossref
Adrienne D Cox & Channing J Der. (1997) Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1333:1, pages F51-F71.
Crossref
Peter F. Lebowitz, Wei Du & George C. Prendergast. (1997) Prenylation of RhoB Is Required for Its Cell Transforming Function but Not Its Ability to Activate Serum Response Element-dependent Transcription. Journal of Biological Chemistry 272:26, pages 16093-16095.
Crossref
Peter F. Lebowitz, Patrick J. Casey, George C. Prendergast & Julia A. Thissen. (1997) Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB. Journal of Biological Chemistry 272:25, pages 15591-15594.
Crossref
Jackson B. Gibbs & Allen Oliff. (1997) THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS. Annual Review of Pharmacology and Toxicology 37:1, pages 143-166.
Crossref
Ch. A. Omer, N. J. Anthony, C. A. Buser-Doepner, A. L. Burkhardt, S. J. Desolms, Ch. J. Dinsmore, J. B. Gibbs, G. D. Hartman, K. S. Koblan, R. B. Lobell, A. Oliff, T. M. Williams & N. E. Kohl. (1997) Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth. BioFactors 6:3, pages 359-366.
Crossref
Carolyn A. Cates, Rodney L. Michael, Keith R. Stayrook, Kevin A. Harvey, Yvette D. Burke, Stephen K. Randall, Pamela L. Crowell & Dring N. Crowell. (1996) Prenylation of oncogenic human PTPcaax protein tyrosine phosphatases. Cancer Letters 110:1-2, pages 49-55.
Crossref
Edith Elliott & Bonnie F. Sloane. (1996) The cysteine protease cathepsin B in cancer. Perspectives in Drug Discovery and Design 6:1, pages 12-32.
Crossref
Patrick J. Casey & Miguel C. Seabra. (1996) Protein Prenyltransferases. Journal of Biological Chemistry 271:10, pages 5289-5292.
Crossref
Semiramis Ayral-Kaloustian & Jerauld S. Skotnicki. 1996. 171 180 .
Hiroshi Maruta & Antony W. BurgessHiroshi Maruta. 1996. Regulation of the RAS Signaling Network. Regulation of the RAS Signaling Network 139 180 .
Hiroshi Maruta & Antony W. BurgessIsabel Sattler & Fuyuhiko Tamanoi. 1996. Regulation of the RAS Signaling Network. Regulation of the RAS Signaling Network 95 137 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.